Morphine intranasal - Hospira
Alternative Names: MNS075; RylomineLatest Information Update: 31 Dec 2021
At a glance
- Originator Innovative Drug Delivery Systems
- Developer Javelin Pharmaceuticals
- Class Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Postoperative pain
Most Recent Events
- 05 Aug 2014 Archimedes Pharma has been acquired by ProStrakan
- 21 Aug 2012 No development reported - Phase-II for Postoperative pain in European Union (Intranasal, spray)
- 21 Aug 2012 No development reported - Phase-III for Postoperative pain in USA (Intranasal, spray)